Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Shanghai HeartCare Medical Technology Corporation Limited

上海心瑋醫療科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6609)

ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2024

FINANCIAL HIGHLIGHTS

	Year ended December 31, 2024 *RMB'000*	Year ended December 31, 2023 *RMB'000*	Period-to-period change
Revenue	**277,899**	232,344	19.6%
Gross profit	**181,716**	163,759	11.0%
Gross profit margin	**65.4%**	70.5%	–5.1 percentage points
Selling & distribution and administrative expenses	**137,805**	153,882	–10.4%
Research and development costs	**58,940**	123,831	–52.4%
Loss before tax	**(11,992)**	(102,920)	–88.3%

BUSINESS HIGHLIGHTS

In the fiscal year 2024, the Company recorded revenue of RMB277.9 million, representing a year-on-year increase of 19.6%. While the Company experienced a decrease on gross profit margin attributable to the price impact from the volume-base procurement and market competition, the Company's loss before taxation sharply narrowed to RMB12.0 million, representing a year-to-year decrease of 88.3%, and the expense rate of the selling and distribution expenses and administrative expenses decreased to 49.6% (2023: 66.2%), as the business scale expands and the effects of cost control and efficiency enhancement measures become evident.

During the year, to adapt to the fast-changing market environment, the Company continuously promotes the upgrade of its neuro-intervention business toward the focus on differentiated treatment devices. Sales volume of acute ischemic stroke treatment devices such as thrombectomy stent, distal access catheter, aspiration catheter and support catheter etc. increased by 45.5%. Revenue of hemorrhagic stroke treatment devices and other interventional access devices increased by 104.2% and 109.4% respectively.

In 2024, the Company's R&D costs stood at RMB58.9 million to support the diversified candidates of neuro-intervention treatment devices. As of the date of this announcement, vascular reconstruction device (NMPA innovative device qualification) and flow diverter device for the treatment of hemorrhagic stroke have obtained NMPA approvals and commenced sales. Furthermore, the Company aims to enhance the competitiveness of key thrombectomy devices (aspiration catheter and thrombectomy stent) and one-stop medical device solutions for different subtypes of acute ischemic stroke. In the following 24 months, the Company expects to launch at least two major neuro-interventional treatment devices, including self-expanding drug stent and carotid artery stent for the treatment of intracranial stenosis to meet the growing demand for stroke treatment in the aging Chinese market.

In the overseas market, the Company has obtained CE or FDA certifications of the thrombectomy stent, balloon guiding catheter, distal access catheter and microcatheter, as well as 26 other registration certificates in other countries or regions. Up to now, the Company has been working on more than 40 product registrations in 10 countries or regions, expanding sales channels, and laying the foundation for achieving long-term goals in overseas sales.

The Board announces the audited consolidated annual results of the Group for the year ended December 31, 2024, together with the comparative figures for the year ended December 31, 2023 as follows:

CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

For the year ended December 31, 2024

	Notes	**2024** ***RMB'000***	2023 *RMB'000*
REVENUE	*4*	**277,899**	232,344
Cost of sales		**(96,183)**	(68,585)
Gross profit		**181,716**	163,759
Other income and gains	*4*	**23,099**	26,108
Other expenses		**(18,313)**	(12,916)
Research and development costs		**(58,940)**	(123,831)
Selling and distribution expenses		**(79,622)**	(79,246)
Administrative expenses		**(58,183)**	(74,636)
Finance costs	*5*	**(1,749)**	(2,158)
Share of loss of an associate		**—**	—
LOSS BEFORE TAX		**(11,992)**	(102,920)
Income tax (expense)/credit	*6*	**(1,630)**	8,908
LOSS AND TOTAL COMPREHENSIVE LOSS FOR THE YEAR		**(13,622)**	(94,012)
Attributable to:			
Owners of the parent		**(13,622)**	(94,012)
LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT			
Basic and diluted (RMB)	*8*	**(0.36)**	(2.47)

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

As at December 31, 2024

	Notes	**As at December 31, 2024** ***RMB'000***	As at December 31, 2023 *RMB'000*
NON-CURRENT ASSETS			
Plant and equipment		**52,568**	69,939
Right-of-use assets		**65,190**	68,572
Goodwill		**9,711**	9,711
Other intangible assets		**33,566**	37,708
Prepayments, other receivables and other assets, non-current		**9,986**	7,398
Financial assets at fair value through profit or loss ("**FVTPL**"), non-current		**9,474**	2,525
Deferred tax assets		**1,956**	—
Investment in an associate		**—**	—
Total non-current assets		**182,451**	195,853
CURRENT ASSETS			
Inventories		**171,114**	146,039
Trade receivables	*9*	**94,713**	76,913
Prepayments, other receivables and other assets, current		**35,785**	53,205
Financial assets at FVTPL		**111,815**	98,934
Cash and bank balances		**601,905**	622,205
Restricted cash		**8,466**	8,096
Total current assets		**1,023,798**	1,005,392
CURRENT LIABILITIES			
Trade and other payables	*10*	**74,441**	51,779
Lease liabilities, current		**7,669**	4,911
Contract liabilities		**315**	3,092
Total current liabilities		**82,425**	59,782

	Notes	As at December 31, 2024 RMB'000	As at December 31, 2023 RMB'000
NET CURRENT ASSETS		**941,373**	945,610
TOTAL ASSETS LESS CURRENT LIABILITIES		**1,123,824**	1,141,463
NON-CURRENT LIABILITIES			
Lease liabilities, non-current		**28,079**	31,472
Government grants		**29,459**	33,895
Deferred tax liabilities		**4,038**	452
Total non-current liabilities		**61,576**	65,819
Net assets		**1,062,248**	1,075,644
EQUITY			
Share capital	*11*	**38,834**	38,834
Treasury shares	*11*	**(45,452)**	(48,999)
Reserves		**1,068,866**	1,085,809
Total equity		**1,062,248**	1,075,644

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

1. CORPORATE AND GROUP INFORMATION

Shanghai HeartCare Medical Technology Corporation Limited (the "**Company**") was incorporated in the People's Republic of China ("**PRC**") on June 16, 2016 as a limited liability company. On December 3, 2020, the Company was converted into a joint stock company with limited liability under the Company Law of the PRC. The registered office and the principal place of the business of the Company is located at Building 38, No. 356, Zhengbo Road, Lingang New District, Pilot Free Trade Zone, Shanghai, the PRC.

The Company was listed on the Main Board of The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") on August 20, 2021.

During the year, the Company and its subsidiaries (the "**Group**") were principally engaged in the research, development, manufacturing and sale of innovative medical devices.

2.1 BASIS OF PREPARATION

These financial statements have been prepared in accordance with IFRS Accounting Standards (which include all International Financial Reporting Standards, International Accounting Standards ("**IASs**") and Interpretations) issued by the International Accounting Standards Board (the "**IASB**") and the disclosure requirements of the Hong Kong Companies Ordinance. They have been prepared under the historical cost convention, except for financial assets at FVTPL. These financial statements are presented in Renminbi ("**RMB**") and all values are rounded to the nearest thousand except when otherwise indicated.

2.2 CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES

The Group has adopted the following revised IFRSs for the first time for the current year's financial statements.

Amendments to IFRS 16	*Lease Liability in a Sale and Leaseback*
Amendments to IAS 1	*Classification of Liabilities as Current or Non-current* (the *"***2020 Amendments***")*
Amendments to IAS 1	*Non-current Liabilities with Covenants* (the "**2022 Amendments**")
Amendments to IAS 7 and IFRS7	*Supplier Finance Arrangements*

The nature and the impact of the revised IFRSs are described below:

(a) Amendments to IFRS 16 specify the requirements that a seller-lessee uses in measuring the lease liability arising in a sale and leaseback transaction to ensure the seller-lessee does not recognize any amount of the gain or loss that relates to the right of use it retains. Since the Group has no sale and leaseback transactions with variable lease payments that do not depend on an index or a rate occurring from the date of initial application of IFRS 16, the amendments did not have any impact on the financial position or performance of the Group.

(b) The 2020 Amendments clarify the requirements for classifying liabilities as current or non-current, including what is meant by a right to defer settlement and that a right to defer must exist at the end of the reporting period. Classification of a liability is unaffected by the likelihood that the entity will exercise its right to defer settlement. The amendments also clarify that a liability can be settled in its own equity instruments, and that only if a conversion option in a convertible liability is itself accounted for as an equity instrument would the terms of a liability not impact its classification. The 2022 Amendments further clarify that, among covenants of a liability arising from a loan arrangement, only those with which an entity must comply on or before the reporting date affect the classification of that liability as current or non-current. Additional disclosures are required for non-current liabilities that are subject to the entity complying with future covenants within 12 months after the reporting period.

The Group has reassessed the terms and conditions of its liabilities as at January 1, 2023 and 2024 and concluded that the classification of its liabilities as current or non-current remained unchanged upon initial application of the amendments. Accordingly, the amendments did not have any impact on the financial position or performance of the Group.

(c) Amendments to IAS 7 and IFRS 7 clarify the characteristics of supplier finance arrangements and require additional disclosure of such arrangements. The disclosure requirements in the amendments are intended to assist users of financial statements in understanding the effects of supplier finance arrangements on an entity's liabilities, cash flows and exposure to liquidity risk. As the Group does not have supplier finance arrangements, the amendments did not have any impact on the Group's financial statements.

2.3 ISSUED BUT NOT YET EFFECTIVE INTERNATIONAL FINANCIAL REPORTING STANDARDS

The Group has not applied the following new and revised IFRSs, that have been issued but are not yet effective, in these financial statements. The Group intends to apply these new and revised IFRSs, if applicable, when they become effective.

IFRS 18	*Presentation and Disclosure in Financial Statements*[3]
IFRS 19	*Subsidiaries without Public Accountability: Disclosures*[3]
Amendments to IFRS 9 and IFRS 7	*Amendments to the Classification and Measurement of Financial Instruments*[2]
Amendments to IFRS 9 and IFRS 7	*Contracts Referencing Nature-dependent Electricity*[2]
Amendments to IFRS 10 and IAS 28	*Sale or Contribution of Assets between an Investor and its Associate or Joint Venture*[4]
Amendments to IAS 21	*Lack of Exchangeability*[1]
Annual Improvements to IFRS Accounting Standards — Volume 11	Amendments to IFRS 1, IFRS 7, IFRS 9, IFRS 10 and IAS 7[2]

1 Effective for annual periods beginning on or after January 1, 2025
2 Effective for annual periods beginning on or after January 1, 2026
3 Effective for annual/reporting periods beginning on or after January 1, 2027
4 No mandatory effective date yet determined but available for adoption

The application of IFRS 18 will have no impact on the consolidated statements of financial position of the Group, but will have impact on the presentation of the consolidated statements of profit or loss and other comprehensive income. Except for IFRS 18, the directors of the Company anticipate that these new and revised IFRS Accounting Standards are not expected to have a material impact on the Group's financial performance and financial position in the foreseeable future.

3. OPERATING SEGMENT INFORMATION

Segment information

For management purposes, the Group is not organised into business units based on their products and only has one reportable operating segment. Management monitors the operating results of the Group's operating segment as a whole for the purpose of making decisions about resource allocation and performance assessment.

4. REVENUE, OTHER INCOME AND GAINS

An analysis of revenue is as follows:

	2024	2023
	RMB'000	*RMB'000*
Revenue from contracts with customers		
Sale of medical devices	**276,931**	232,344
Revenue from services provided	**968**	—
Total	**277,899**	232,344

Revenue from contracts with customers

(a) Disaggregated revenue information

	2024	2023
	RMB'000	*RMB'000*
Geographical markets		
Mainland China	**269,504**	231,273
Others	**8,395**	1,071
Total	**277,899**	232,344
Timing of revenue recognition		
Goods transferred at a point in time	**277,899**	232,344

The following table shows the amounts of revenue recognised in the current reporting period that were included in the contract liabilities at the beginning of the reporting period:

	2024	2023
	RMB'000	*RMB'000*
Sale of medical devices	**2,293**	3,258

(b) Performance obligations

Information about the Group's performance obligations is summarised below:

Sale of medical devices

The performance obligation is satisfied upon transfer of the products to the logistics companies or acceptance by the customer. Payment is made in advance or due within 30 to 90 days from delivery. Some contracts provide customers with volume rebates which give rise to variable consideration subject to constraint.

An analysis of other income and gains is as follows:

	2024	2023
	RMB'000	*RMB'000*
Other income		
Government grants *(note)*	**8,793**	11,211
Bank interest income	**8,766**	11,195
Total other income	**17,559**	22,406
Gains		
Foreign exchange gains, net	**1,173**	1,403
Fair value gains on financial assets at FVTPL	**4,367**	934
Gain on disposal of items of property, plant and equipment	**—**	84
Gain on disposal of a subsidiary	**—**	1,281
Total gains	**5,540**	3,702
Total other income and gains	**23,099**	26,108

Note:

The government grants mainly represent subsidies received from local government authorities for the purpose of compensation for expenditure arising from research and clinical trial activities, awards for new medical device development and capital expenditure incurred on certain projects.

5. FINANCE COSTS

	2024	2023
	RMB'000	*RMB'000*
Interest on lease liabilities	**1,749**	2,128
Interest on bank loans	**—**	30
Total	**1,749**	2,158

6. INCOME TAX

The provision for corporate income tax in Mainland China is based on the statutory rate of 25% of the assessable profits as determined in accordance with the PRC Corporate Income Tax Law which was approved and became effective on January 1, 2008.

Weiming Medical Devices (Shanghai) Co., Ltd. ("**Weiming**") was accredited as a "Key industry enterprise in the Lingang New Area of China (Shanghai) Pilot Free Trade Zone" in January 2021 and has been entitled to a preferential income tax rate of 15% for a five-year period since 2020. In addition, Weiming was accredited as a "High and New Technology Enterprise" in December 2024 and therefore is entitled to a preferential tax rate of 15% for a three-year period since 2024.

The Company was accredited as a "High and New Technology Enterprise" in November 2021 and the qualification as a High and New Technology Enterprise of the Company was renewed in December 2024, and therefore the Company is entitled to a preferential tax rate of 15% for the years ended 31 December 2023 and 2024.

Nanjing SealMed Medical Technology Co., Ltd. ("**SealMed**") was accredited as a "High and New Technology Enterprise" in December 2023 and therefore is entitled to a preferential tax rate of 15% for a three-year period since 2023.

The qualification as a High and New Technology Enterprise will be subject to review by the relevant tax authority in Mainland China for every three years and the Company, Weiming and SealMed should self-evaluate whether they meet the criteria of High and New Technology Enterprise each year.

Pursuant to Caishui [2018] circular No. 76, the Company and its certain subsidiaries which were accredited as "Technology-based Small and Medium-sized Enterprises" can carry forward their unutilised tax losses for up to ten years. This extension of the expiration period applies to all the unutilised tax losses that were carried forward by the entities at the effective date of the tax circular.

Pursuant to the relevant EIT Law, the Company and its certain subsidiaries enjoyed a super deduction of 200% on qualifying research and development expenditures during the year ended December 31, 2024.

The income tax credit of the Group for the reporting period is analysed as follows:

	2024	2023
	RMB'000	*RMB'000*
Current tax:		
Credit for the year	**—**	—
Deferred tax	**1,630**	(8,908)
	1,630	(8,908)

A reconciliation of the tax expense applicable to loss before tax at the statutory rate to the tax expense at the effective tax rate is as follows:

	2024	2023
	RMB'000	*RMB'000*
Loss before tax	**(11,992)**	(102,920)
Tax at the applicable tax rate of 25%	**(2,998)**	(25,730)
Lower tax rate enacted by local authority	**448**	6,621
Effect on opening deferred tax of decrease in rates	**—**	(3,744)
Expenses not deductible for tax purpose	**1,159**	5,520
Additional deductible allowance for research and development expenses	**(6,354)**	(11,172)
Deductible temporary differences and tax losses not recognised	**12,356**	30,892
Utilization/recognition of deductible temporary differences and tax losses previously not recognized	**(2,981)**	(11,295)
Tax charge/(credit) at the Group's effective rate	**1,630**	(8,908)

The Group has accumulated tax losses that are not recognised as deferred tax assets of RMB686,522,000 as at December 31, 2024 (2023: RMB675,809,000), that will expire in two to ten years for offsetting against future taxable profits of the entities in which the losses arose. The Group has deductible temporary differences of RMB82,502,000 as at December 31, 2024 (2023: RMB70,875,000), which are mainly related to government grants and share of loss of an associate.

7. DIVIDENDS

No dividend has been paid or declared by the Company during the year (2023: Nil).

8. LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT

The calculation of the basic loss per share amount is based on the loss for the year attributable to ordinary equity holders of the parent, and the weighted average number of ordinary shares of 37,768,407 (2023: 38,077,150) outstanding during the year.

No adjustment has been made to the basic loss per share amounts presented for the years ended December 31, 2024 and 2023 in respect of a dilution as the impact of the share award schemes had an anti-dilutive effect on the basic loss per share amounts presented.

The calculations of basic and diluted loss per share are based on:

	2024	2023
Loss		
Loss attributable to ordinary equity holders of the parent, used in the basic loss per share calculation (RMB'000)	**(13,622)**	(94,012)
Shares		
Weighted average number of ordinary shares outstanding during the year used in the basic loss per share calculation	**37,768,407**	38,077,150
Loss per share (basic and diluted) (RMB per share)	**(0.36)**	(2.47)

9. TRADE RECEIVABLES

	2024	2023
	RMB'000	*RMB'000*
Trade receivables	**97,381**	78,659
Impairment	**(2,668)**	(1,746)
Net carrying amount	**94,713**	76,913

The Group's trading terms with its customers are payment in advance or on credit. The credit period is generally 30 to 90 days for major customers. Each customer has a maximum credit limit. The Group does not hold any collateral or other credit enhancements over its trade receivable balances. Trade receivables are non-interest-bearing.

An ageing of the trade receivables as at the end of each of the reporting period, based on the invoice date and net of loss allowance, is as follows:

	2024	2023
	RMB'000	*RMB'000*
Within 6 months	**94,713**	76,913

The movements in the loss allowance for impairment of trade receivables are as follows:

	2024	2023
	RMB'000	*RMB'000*
At beginning of year	**1,746**	816
Impairment losses	**922**	930
At end of year	**2,668**	1,746

Set out below is the information about the credit risk exposure on the Group's trade receivables using a provision matrix:

As at December 31, 2024

	Current
Expected credit loss rate	2.74%
Gross carrying amount (RMB'000)	97,381
Expected credit losses (RMB'000)	2,668

As at December 31, 2023

	Current
Expected credit loss rate	2.22%
Gross carrying amount (RMB'000)	78,659
Expected credit losses (RMB'000)	1,746

10. TRADE AND OTHER PAYABLES

	2024	2023
	RMB'000	*RMB'000*
Trade payables	**16,916**	3,667
Accrued expenses	**12,348**	6,872
Payroll payable	**19,623**	16,339
Other tax payables	**9,896**	7,431
Other payables	**14,941**	11,427
Advance payments received for subscription of share awards *(note)*	**717**	6,043
Total	**74,441**	51,779

Note: The amount represented payments received in advance from employees for subscribing share awards granted under the 2021 H Share Incentive Scheme.

An ageing analysis of the trade payables as at the end of the reporting period, based on the invoice date, is as follows:

	2024	2023
	RMB'000	*RMB'000*
Within 3 months	**14,747**	2,143
3 to 6 months	**1,008**	201
6 to 12 months	**276**	301
1 to 2 years	**501**	1,022
More than 2 years	**384**	—
Total	**16,916**	3,667

Trade and other payables are unsecured, non-interest-bearing and repayable on demand.

11. SHARE CAPITAL/TREASURY SHARES

Shares

	2024	2023
	RMB'000	*RMB'000*
Issued and fully paid:		
38,834,408 (2023: 38,834,408) ordinary shares of RMB1.00 each	**38,834**	38,834

Treasury shares

On November 1, 2021, shareholders of the Group approved the adoption of the 2021 H share incentive scheme (the "**2021 H Share Incentive Scheme**"). Pursuant to the 2021 H Share Incentive Scheme, 115,100 (2023: 275,000) shares were purchased on the Hong Kong Stock Exchange by the trustee under the scheme at a total consideration of RMB2,644,000 (2023: RMB6,436,000) during the year.

MANAGEMENT DISCUSSION AND ANALYSIS

I. BUSINESS

Overview

We are an innovative medical device company committed to improving the accessibility of innovative medical technologies and protecting lives and health. We have established a pioneering leadership position in China's neuro-interventional market and successfully provided the first domestic one-stop solution for stroke treatment and prevention. Leveraging our advantage in R&D, manufacturing and commercialization, we strive to fulfill the unmet needs of clinicians and patients in the fields with tremendous opportunities, redefine the standard of care, reduce mortality rate, and improve prognosis by continuously launching innovative medical devices.

In the fiscal year 2024, the Company recorded revenue of RMB277.9 million, representing a year-on-year increase of 19.6%. While the Company experienced the decrease on gross profit margin attributable to the price impact from the volume-base procurement and market competition, the Company's loss before taxation sharply narrowed to RMB12.0 million, representing a year-to-year decrease of 88.3%, and expense rate of the selling and distribution expenses and administrative expenses decreased to 49.6% (2023: 66.2%), as the business scale expands and the effects of cost control and efficiency enhancement measures become evident.

During the year, to adapt to the fast-changing market environment, the Company continuously promotes the upgrade of its neuro-intervention business toward the focus on differentiated treatment devices. Sales volume of acute ischemic stroke treatment devices such as thrombectomy stent, distal access catheter, aspiration catheter and support catheter etc. increased by 45.5%. Revenue of hemorrhagic stroke treatment devices and other interventional access devices increased by 104.2% and 109.4% respectively.

In 2024, the Company's R&D costs stood at RMB58.9 million to support the diversified candidates of neuro-intervention treatment devices. As of the date of this announcement, vascular reconstruction device (NMPA innovative device qualification) and flow diverter device for the treatment of hemorrhagic stroke have obtained NMPA approvals and commenced sales. Furthermore, the Company aims to enhance the competitiveness of key thrombectomy devices (aspiration catheter and thrombectomy stent) and one-stop medical device solutions for different subtypes of acute ischemic stroke. In the following 24 months, the Company expects to launch at least two major neuro-interventional treatment devices, including self-expanding drug stent and carotid artery stent for the treatment of intracranial stenosis to meet the growing demand for stroke treatment in the aging Chinese market.

In the overseas market, the Company has obtained CE or FDA certifications of the thrombectomy stent, balloon guiding catheter, distal access catheter and microcatheter, as well as 26 other registration certificates in other countries or regions. The Company is currently working on more than 40 product registrations in 10 countries or regions, expanding sales channels, and laying the foundation for achieving long-term goals in overseas sales.

Products and Pipeline

As of the date of this announcement, we have 31 device products approved by NMPA, three device products approved by FDA and one product obtained CE Mark.

The following diagram summarizes the development status of our neuro-interventional pipeline including approved products and broad product pipelines in the late-stage of R&D covering acute ischemic stroke and neurovascular stenosis treatment, hemorrhagic stroke treatment, ischemic stroke prevention, interventional access and peripheral interventional devices as of the date of this announcement:



* *Eligible for NMPA Green Channel*

FDA and Conformité Européenne (CE) Pipeline



Our Key Neuro-interventional Products and Product Candidates

Ischemic Stroke Thrombectomy Devices

Core Product — Captor® Thrombectomy Stent ("**Captor**") is the first domestic thrombectomy stent retriever with multi-markers approved by NMPA. Sales in China started in December 2020. As of the date of this announcement, we have upgraded Captor by adding more product models with stents of varying lengths and diameters. Depending on the occluded blood vessel diameter and thrombus size, physicians may choose the stent retriever with the proper length and size, out of a selection of nine product models. We are evaluating the opportunities for upgrading Captor for indication expansion. Further, we are evaluating the opportunities to market Captor overseas and may apply for its registration in the United States subject to the results of our evaluation. This product has obtained CE Mark.

WE MAY NOT BE ABLE TO ULTIMATELY DEVELOP NEW INDICATION AND SPECIFICATIONS AND EXPAND OVERSEAS MARKET FOR OUR CAPTOR SUCCESSFULLY.

Aspiration Catheter is used in the aspiration thrombectomy procedure to retrieve the thrombus and restore blood flow in occluded cerebral vessels for patients with acute ischemic stroke with large vessel occlusion ("**AIS-LVO**"). Aspiration thrombectomy can be performed not only on a stand-alone basis, but also together with stent retrieving thrombectomy in accordance with the patient's symptoms. We have obtained NMPA approval for our aspiration catheter and sales commenced in 2022.

Carotid artery heavy load thrombus aspiration technique (CATCH) combines our 8F large-inner lumen Aspiration Catheter ("**088 Aspiration Catheter**") with an approved aspiration indication. With a larger cross-sectional area, 088 Aspiration Catheter provides stronger negative pressure and thrombus accommodation space, enhancing recanalization rates. This allows physicians to precisely and rapidly remove thrombi during acute stroke thrombectomy, improving patient outcomes and gaining widespread clinical recognition.

Besides Captor and Aspiration Catheter, our **Aspiration Pump** for the treatment of ischemic stroke has obtained NMPA approval, and we had a product portfolio covering stents and aspiration thrombectomy procedure for the emergency treatment of different subtypes of acute ischemic stroke.

Intracranial Stenosis Treatment Devices

Intracranial Balloon Dilatation Catheter and Carotid Artery Balloon Dilatation Catheter

Both intracranial balloon dilatation catheter and carotid artery balloon dilatation catheter are designed to be used in balloon angioplasty procedures for patients with intracranial stenosis, with the former used in intracranial vessels and the latter in the carotid artery. The balloon dilatation catheters are designed to be passed into the narrowed artery and push the plaque to the sides of the artery and improve the patient's blood flow. We received the NMPA approvals for our intracranial balloon dilatation catheter and carotid artery balloon dilatation catheter in 2021.

Embolization Protection System is used in interventional procedures for peripheral, coronary artery and carotid artery to capture and remove debris that dislodges during the procedures. It can help prevent the debris from blocking smaller vessels, which may result in procedural complications. We have obtained NMPA approval for our embolization protection system.

Intracranial Drug-eluting Stent ("**Intracranial DES**") is a stent placed into narrowed and diseased arteries that slowly releases an anti-proliferative drug to block cell proliferation. The stent is usually placed within arteries during an angioplasty procedure. Drug-eluting stents generally consist of three parts — the stent platform, a polymer coating that binds the drug to the stent and releases drug, and the drug. As at the date of the announcement, patient enrollment for clinical trial of our intracranial DES has been completed.

Carotid Artery Stent is an endovascular implantable device designed for the treatment of extracranial carotid artery stenosis, typically deployed via percutaneous transluminal angioplasty (PTA) with embolic protection. As at the date of the announcement, our carotid artery stent is in registration stage.

Hemorrhagic Stroke Treatment Devices

Vascular Reconstruction Device is used in aneurysm coiling procedures for patients with aneurysm. It is designed for bridging the neck of aneurysm to support the coils placed in the aneurysm. Our vascular reconstruction device has been approved by NMPA in October 2024, and sales has commenced.

Flow Diverter Device is a neurovascular stent placed in the blood vessel of an aneurysm, which can divert blood flow away from the aneurysm. Over time, blood flow into the aneurysm may slow down and the aneurysm may shrink, thus healing the blood vessel. As at the date of this announcement, our flow diverter device has obtained NMPA approval.

Ischemic Stroke Prevention Devices

Core Product — LAA Occluder is a stroke prevention device designed to be permanently implanted at the opening of the LAA of patients with non-valvular atrial fibrillation (AF) to prevent thrombus escaping from the LAA, thus causing embolization. LAA Occlusion is a one-time surgical therapy with proven efficacy, in particular for the patient who is not suitable for long-term oral anticoagulation therapy and has a higher risk for bleeding complications. We have obtained NMPA approval and commenced sales in 2022.

Vascular Access Devices

We are also developing various vascular access devices for use in interventional procedures. As of the date of this announcement, we have obtained NMPA approvals for **Distal Access Catheter, Microcatheter, Balloon Guiding Catheter, Vascular Closure Device, Support Catheter, Neuro-Interventional Microcatheter, Neuro-interventional Micro Guidewire, Microcatheter for Coiling, Microcatheter for Flow Diverter Device** and **Navigation Catheter.**

In addition, we have several other product candidates in the design stage, which further supplement our full-set product portfolio for the treatment and prevention of stroke. For details of our products and product candidates, please refer to the Company's Prospectus.

Research and Development

The Company's product R&D aims to build a high-quality product portfolio with market competitiveness. Capitalizing on existing R&D platforms, certain products we developed are qualified for NMPA priority review. Meanwhile, we formed a multi-level product matrix through continuously iterating products approved for marketing, so as to meet the clinical needs.

As of the date of this announcement, we had 254 registered patents, including 126 invention patents, 115 utility models and 13 industrial design patents. As of the date of this announcement, we also had 88 pending patents applications, including 76 invention patents, 11 utility models and 1 industrial design patents.

Manufacturing

In terms of manufacturing, we continuously improve our product quality and competitive advantage based on a stable and efficient supply chain.

As of the date of this announcement, we have two production facilities in Shanghai Lingang New Area and Nanjing Jiangbei New Area, which can ensure a sufficient supply of products.

Commercialization

As of the date of this announcement, we have established an extensive distribution network covering over 2,500 hospitals across all provinces nationwide other than Hong Kong and Macau.

Meanwhile, academic exchange platforms elaborately built by us contribute to our brand image and influence in the market through diversified channels and digital media, laying the foundation for long-term and stable revenue growth.

Future and Outlook

We aim to become the leader in the neuro-interventional medical device market in China, and to develop into a competitive domestic device company in several innovative medical device markets within China.

We plan to implement the following strategies to achieve this goal:

- improve our brand recognition as a comprehensive neuro-interventional device solution provider in the market, expand sales of our commercialized neuro-interventional devices and rapidly advance our product candidates into commercialization;

- further enhance our manufacturing capabilities to ensure reliability of our product supply; and

- promote the development of innovative medical devices in emerging therapeutic fields with high potential growth market to form a second business unit with a competitive commercialized product portfolio in addition to our neuro-interventional business.

The Company also proposed to apply to the relevant PRC authorities for the issuance of A shares to be listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange, please refer to the Company's announcements dated October 10, 2022, November 9, 2022, October 16, 2023 and October 17, 2024 and circulars dated October 24, 2022, October 20, 2023 and October 21, 2024 for further details.

II. FINANCIAL REVIEW

Overview

The following discussion is based on, and should be read in conjunction with, the financial information and the notes included elsewhere in this announcement.

Revenue

For the year ended December 31, 2024, our revenue was mainly generated from the sales of our commercialized neuro-interventional devices.

Revenue increased by 19.6% from RMB232.3 million for the year ended December 31, 2023 to RMB277.9 million for the year ended December 31, 2024. The increase in revenue was mostly attributable to the continuous growth in sales of our acute ischemic stroke (AIS) treatment devices, and an increase of sales of hemorrhagic stroke treatment devices and access devices. Meanwhile, overseas revenue has significantly improved after a number of product registration approval by local bureau.

Cost of Sales

Cost of sales increased from RMB68.6 million for the year ended December 31, 2023 to RMB96.2 million for the year ended December 31, 2024, which was in line with the increase in our revenue.

Gross Profit and Gross Profit Margin

As a result of the foregoing, our gross profit increased from RMB163.8 million for the year ended December 31, 2023 to RMB181.7 million for the year ended December 31, 2024. Gross profit margin is calculated as gross profit divided by revenue. Our gross profit margin decreased from 70.5% for the year ended December 31, 2023 to 65.4% for the year ended December 31, 2024, primarily attributed to the price impact from the volume-base procurement and market competition.

Other Income and Gains

Other income and gains decreased from RMB26.1 million for the year ended December 31, 2023, to RMB23.1 million for the year ended December 31, 2024, primarily attributable to the decrease in our government grants and bank interest income.

Research and Development Costs

Research and development costs decreased from RMB123.8 million for the year ended December 31, 2023, to RMB58.9 million for the year ended December 31, 2024, primarily due to (i) the decrease in raw materials and consumables incurred for the trial manufacture of our pipeline candidates; (ii) the reduction of number of staff of the R&D team; and (iii) the reduction in third party contracting costs.

The following table sets forth a breakdown of our research and development costs:

	Year ended December 31, 2024		Year ended December 31, 2023	
	RMB million	***%***	*RMB million*	*%*
Staff costs	**22.6**	**38.4**	43.9	35.5
Depreciation	**8.0**	**13.6**	8.2	6.6
Third party contracting costs	**20.4**	**34.6**	35.9	29.0
Raw materials and consumables	**5.5**	**9.3**	28.0	22.6
Others	**2.4**	**4.1**	7.8	6.3
Total	**58.9**	**100.0**	123.8	100.0

Administrative Expenses

Administrative expenses decreased from RMB74.6 million for the year ended December 31, 2023 to RMB58.2 million for the year ended December 31, 2024, primarily attributed to a decrease in professional service fees.

Selling and Distribution Expenses

Selling and distribution expenses increased from RMB79.2 million for the year ended December 31, 2023 to RMB79.6 million for the year ended December 31, 2024.

Other Expenses

For the year ended December 31, 2024, we incurred other expenses of RMB18.3 million, which was primarily in relation to the impairment of inventories and losses related to land-use-right deposit.

Finance Costs

Finance costs decreased from RMB2.2 million for the year ended December 31, 2023, to RMB1.7 million for the year ended December 31, 2024.

Borrowings and Gearing Ratio

As at December 31, 2024 the Group has not incurred any outstanding borrowing. The gearing ratio (calculated by dividing the sum of borrowings and lease liabilities by total equity) of the Group as at December 31, 2024 was 3.4% (for the year ended December 31, 2023: 3.4%).

Liquidity and Financial Resources

We primarily rely on capital contributions by our shareholders, equity financing as well as cash generated from our sales revenue of existing commercialized medical device products as major sources of liquidity. As part of our treasury policy, our management monitors and maintains a level of cash and bank balances deemed adequate to finance our operations and mitigate the effects of fluctuations in cash flows. As our business develops and expands, we expect to generate more cash from our operating activities, through increasing sales revenue of the existing commercialized products and by launching new products.

Our cash and bank balances as of December 31, 2024 were RMB601.9 million, representing a decrease of RMB20.3 million compared to RMB622.2 million as of December 31, 2023.

Our net current assets as of December 31, 2024 were RMB941.4 million, as compared to RMB945.6 million as of December 31, 2023.

Capital Expenditure

For the year ended December 31, 2024, our total capital expenditure amounted to approximately RMB5.2 million as compared to a capital expenditure of RMB49.3 million for the year ended December 31, 2023, the capital expenditure was primarily used in the plant and equipment.

Contingent Liabilities

As of December 31, 2024, the Group did not have any material contingent liabilities.

Significant Investments, Material Acquisitions and Disposals

The Group did not have material acquisitions and disposals of subsidiaries, associates and joint ventures, or have any significant investment accounting for more than 5% of the Group's total assets for the year ended December 31, 2024.

Pledge of Assets

As of December 31, 2024, the Group had no pledge of assets.

Foreign Exchange Exposure

We are exposed to foreign currency risk mainly arising from cash at bank denominated in USD and HKD. We currently do not have a foreign currency hedging policy. However, our management monitors foreign exchange exposure and will consider appropriate hedging measures in the future should the need arise.

Future Plans for Material Investments or Capital Assets

We had not authorized any plan for the material investments or acquisition of capital asset as of the date of this announcement.

HUMAN RESOURCES

As of December 31, 2024, we had 344 full-time employees in total.

The remuneration policy for the Directors and senior management is based on their responsibility and general market conditions. Any discretionary and performance bonus are linked to the general performance of the Group and the individual performances of the Directors and senior management.

In compliance with the relevant PRC labor laws, we enter into individual employment contracts with our employees covering matters such as terms, wages, bonuses, employee benefits, workplace safety, confidentiality obligations and grounds for termination.

To remain competitive in the labor market, we provide various incentives and benefits to our employees. We invest in continuing education and training programs, including internal and external training, for our management staff and other employees to upgrade their skills and knowledge. We also provide competitive salaries and stock incentive plans to our employees especially key employees. We believe our benefits, working environment and development opportunities for our employees have contributed to good employee relations and employee retention.

SUBSEQUENT EVENTS AFTER THE REPORTING PERIOD

There is no material subsequent event undertaken by the Company or by the Group after the Reporting Period and up to the date of this announcement.

PRE-EMPTIVE RIGHTS

There are no provisions for pre-emptive rights under the articles of association of the Company, or the laws of the PRC, which would oblige the Company to offer new shares of the Company on a pro-rata basis to its existing shareholders.

SUFFICIENCY OF PUBLIC FLOAT

According to the information that is publicly available to the Company and within the knowledge of the Board, as at the date of this announcement, the Company has maintained the public float as required under the Listing Rules.

PURCHASE, SALE OR REDEMPTION OF LISTED SECURITIES OF THE COMPANY

Neither the Company nor any of its subsidiaries have purchased, sold or redeemed any of the Company's listed securities (including sale of treasury shares, if any) during the Reporting Period. The Company does not have any treasury shares as defined under Listing Rules as at December 31, 2024.

USE OF PROCEEDS FROM LISTING

The H Shares of the Company were first listed on the Main Board of the Stock Exchange on August 20, 2021. Net proceeds received from our Global Offering aggregated approximately HK$1,014.8 million. Reference is made to the Company's prospectus dated August 10, 2021.

Details of the planned applications of net proceeds from the Listing were disclosed in the Prospectus. As at December 31, 2024, the utilization of the net proceeds from the Global Offering are as follows:

Use of proceeds	Planned applications *(HK$ million)*	Actual utilization as at December 31, 2023 *(HK$ million)*	Utilization during the Reporting Period *(HK$ million)*	Actual utilization as at December 31, 2024 *(HK$ million)*	Balance as at December 31, 2024 *(HK$ million)*	Expected timeline for full utilization of the unutilized net proceeds[1]
R&D, manufacturing and marketing of our core products	459.7	267.3	84.4	351.7	108.0	December 31, 2026
R&D, product registration, manufacturing and marketing of other product candidates in our pipeline	404.9	223.1	47.4	270.5	134.4	December 31, 2026
Improvements to our R&D capacities and our continued expansion of product portfolio through internal research	48.7	48.7	—	48.7	—	—
Working capital and general corporate purposes	101.5	101.5	—	101.5	—	—
Total	**1,014.8**	**640.6**	**131.8**	**772.4**	**242.4**	

Note:

1. The expected timeline to use the remaining proceeds is prepared based on the best estimate made by the Group, which is subject to change according to the current and future development of the market condition.

FINAL DIVIDEND

The Board does not recommend the payment of a final dividend for the Reporting Period (2023: Nil).

ANNUAL GENERAL MEETING

The Company will hold the annual general meeting (the "**AGM**") on Monday, May 26, 2025. A notice of convening the AGM will be published on the websites of the Stock Exchange at www.hkexnews.hk and the Company at www.heartcare.com.cn, and dispatched to the Shareholders in the manner as required by the Listing Rules in due course.

CLOSURE OF REGISTER OF MEMBERS OF H SHARES AND ASCERTAINING OF ELIGIBILITY FOR ATTENDING THE AGM

The register of members of H Shares the Company will be closed from Saturday, April 26, 2025 to Monday, May 26, 2025 (both days inclusive), during which period no transfer of H Shares will be registered. In order to qualify for attending and voting at the AGM, all transfer documents accompanied by the relevant share certificate(s) must be lodged with the Company's H Share registrar, Computershare Hong Kong Investor Services Limited at Shops 1712–1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong no later than 4:30 p.m. on Friday, April 25, 2025.

CORPORATE GOVERNANCE PRACTICES

The Company recognizes the importance of good corporate governance for enhancing the management of the Company as well as preserving the interests of the shareholders of the Company as a whole. The Company has adopted the code provisions as set out in the CG Code as its own code to govern its corporate governance practices. Except for code provision C.2.1 set out below, in the opinion of the Directors, the Company has complied with all the code provisions as set out in Part 2 of the CG Code during the Reporting Period.

Under code provision C.2.1 of Part 2 of the CG Code, the roles of chairman and chief executive should be separate and should not be performed by the same individual. Mr. Wang Guohui is the chairman of the Board and chief executive officer of the Company. With extensive experience in the medical devices industry and having served in the Company as the general manager since the very early stage of the Company, Mr. Wang is in charge of overall management of the Company. Despite the fact that the roles of our chairman of the Board and our chief executive officer are both performed by Mr. Wang which constitutes a deviation from code provision C.2.1 of Part 2 of the CG Code, the Board considers that vesting the roles of both chairman of the Board and chief executive officer all in Mr. Wang has the benefit of ensuring consistent leadership and more effective and efficient overall strategic planning of the Company. The balance of power and authority is ensured by the operation of our Board, which comprises experienced and diverse individuals. The Board currently comprises three non-executive Directors and three independent non-executive Directors as compared to three executive Directors. Therefore, the Board possesses a strong independent element in its composition. The Board will continue to review and monitor the practices of the Company with an aim of maintaining a high standard of corporate governance.

MODEL CODE FOR SECURITIES TRANSACTIONS

The Company has adopted the Model Code as its own code of conduct regarding dealings in the securities of the Company by the Directors, Supervisors and senior management who, because of their office or employment, are likely to possess inside information in relation to Company or its securities.

Upon specific enquiry, all Directors and Supervisors confirmed that they have complied with the Model Code during the Reporting Period. In addition, the Company is not aware of any non-compliance with the Model Code by the senior management of the Group during the Reporting Period.

REVIEW OF ANNUAL RESULTS AND ANNUAL REPORT

The Audit Committee currently has three members comprising two independent non-executive Directors, being Mr. Gong Ping (chairman) and Mr. Feng Xiangqian, and one non-executive Director, being Mr. Ding Kui, with terms of reference in compliance with Rule 3.21 of the Listing Rules. The Audit Committee has considered and reviewed the accounting principles and practices adopted by the Group and has discussed matters in relation to internal controls, risk management and financial reporting with the management, including the review of the audited consolidated financial statements and the annual report of the Group for the Reporting Period.

The Audit Committee, together with the management and external auditor of the Company, considers that the audited consolidated financial statements of the Group for the Reporting Period are in compliance with the relevant accounting standards, rules and regulations and appropriate disclosures have been duly made.

Scope of Work of Ernst & Young

The figures in respect of the Group's consolidated statement of financial position, consolidated statement of profit or loss and other comprehensive income and the related notes thereto for the Reporting Period as set out in this announcement have been agreed by the Company's auditors, Ernst & Young (the "**Auditors**"), to the amounts set out in the Group's audited consolidated financial statements for the Reporting Period.

The work performed by the Auditors in this respect did not constitute an assurance engagement in accordance with Hong Kong Standards on Auditing, Hong Kong Standards on Review Engagements or Hong Kong Standards on Assurance Engagements issued by the Hong Kong Institute of Certified Public Accountants and consequently, no assurance has been expressed by the Auditors on this announcement.

PUBLICATION OF ANNUAL RESULTS AND 2024 ANNUAL REPORT

This announcement is published on the websites of the Stock Exchange (www.hkexnews.hk) and the Company (www.heartcare.com.cn). The annual report of the Company for the Reporting Period containing all the information required by the Listing Rules will be published on the above websites in due course.

DEFINITIONS

In this announcement, unless the context otherwise requires, the following expressions shall have the following meanings:

"AGM"	The forthcoming annual general meeting of the Company to be held on Monday, May 26, 2025
"Audit Committee"	the audit committee of the Board
"Board"	the board of directors of the Company
"CG Code"	the Corporate Governance Code set out in Appendix C1 to the Listing Rules
"China" or "PRC"	the People's Republic of China, but for the purpose of this announcement and for geographical reference only and except where the context requires, excluding Hong Kong, Macau Special Administrative Region and Taiwan
"Company"	Shanghai HeartCare Medical Technology Corporation Limited (上海心瑋醫療科技股份有限公司), a joint stock limited liability company incorporated in the PRC, whose H Shares are listed on the Hong Kong Stock Exchange (Stock Code: 6609)
"Director(s)"	the director(s) of the Company or any one of them
"FDA"	the U.S. Food and Drug Administration
"Global Offering"	has the meaning as ascribed to it under the Prospectus
"Group", "our", "we" or "us"	the Company and its subsidiaries

"H Share(s)"	the overseas listed foreign shares with a nominal value of RMB1.00 each in the share capital of the Company, which are listed on the Hong Kong Stock Exchange and subscribed for and traded in Hong Kong dollars
"Hong Kong"	the Hong Kong Special Administrative Region of the PRC
"Hong Kong dollars", "HKD" or "HK$"	Hong Kong dollars and cents respectively, the lawful currency of Hong Kong
"IFRS"	International Financial Reporting Standards, as issued from time to time by the International Accounting Standards Board
"Listing"	the listing of the Shares on the Main Board of the Stock Exchange
"Listing Rules"	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, as amended, supplemented or otherwise modified from time to time
"Model Code"	the Model Code for Securities Transactions by Directors of Listed Issuers set out in Appendix C3 to the Listing Rules
"NMPA"	the National Medical Products Administration (國家藥品監督管理局) and its predecessor, the China Food and Drug Administration (國家食品藥品監督管理總局) or the CFDA
"Prospectus"	the prospectus of the Company dated August 10, 2021, in relation to the Global Offering
"R&D"	research and development
"Reporting Period"	the year ended December 31, 2024
"RMB" or "Renminbi"	Renminbi, the lawful currency of the PRC
"Share(s)"	share(s) in the share capital of the Company, with a nominal value of RMB1.00 each, comprising the Unlisted Shares and H Shares
"Shareholder(s)"	holder(s) of the Share(s)

"Stock Exchange"	The Stock Exchange of Hong Kong Limited
"Subsidiary(ies)"	has the meaning ascribed thereto under the Listing Rules
"Supervisor(s)"	the supervisor(s) of the Company
"Unlisted Share(s)"	the ordinary shares in the share capital of the Company, with a nominal value of RMB1.00 each, which are subscribed and credited as fully paid up in Renminbi
"United States" or "U.S."	the United States of America, its territories, its possessions and all areas subject to its jurisdiction
"USD"	United States dollars, the lawful currency of the United States
"%"	per cent

By Order of the Board
Shanghai HeartCare Medical Technology Corporation Limited
Wang Guohui
Chairman of the Board

Shanghai, March 27, 2025

As at the date of this announcement, the executive Directors are Mr. Wang Guohui, Ms. Zhang Kun and Mr. Wei Jiawei; the non-executive Directors are Mr. Ding Kui, Mr. Chen Shaoxiong and Mr. Chen Gang; and the independent non-executive Directors are Mr. Guo Shaomu, Mr. Feng Xiangqian and Mr. Gong Ping.